Details of the Drug Formulations

General Information of Drug (ID: DM20VSK)

• Drug Name: Istradefylline Drug Info
• Synonyms: KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]
Substance use disorder	6C4Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 5311037
  ChEBI ID: CHEBI:134726
  CAS Number: 155270-99-8
  TTD ID: D0F4ZY
  VARIDT ID: DR00611
  INTEDE ID: DR0892
  ACDINA ID: D01185

Full List of Drug Formulations Containing This Drug

Istradefylline 20 mg tablet

Company	Formulation ID	FDA Description
Kyowa Kirin	F23204	Crospovidone; Lactose Monohydrate; Magnesium Stearate; Microcrystalline Cellulose; Polyvinyl Alcohol; Hypromellose; Polyethylene Glycol 3350; Titanium Dioxide; Triacetin; Iron Oxide Red; Iron Oxide Yellow; Carnauba Wax

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)